TXG (10x Genomics, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TXG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Serge Saxonov | Chief Executive Officer | G | — | — |
| 2026-08-28 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-08-26 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2026-08-26 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-08-26 | SHEHNAAZ SULIMAN | Director | Sell | — | — |
| 2026-08-26 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2026-08-24 | Serge Saxonov | Chief Executive Officer | G | — | — |
| 2026-08-17 | Sarah A. Teichmann | Director | Sell | — | — |
| 2026-08-13 | JOHN R STUELPNAGEL | Director | Sell | — | — |
| 2026-06-24 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-06-18 | SHEHNAAZ SULIMAN | Director | Sell | — | — |
| 2026-06-08 | SHEHNAAZ SULIMAN | Director | A | — | — |
| 2026-06-08 | ALAN MATEO | Director | A | — | — |
| 2026-06-08 | JOHN R STUELPNAGEL | Director | A | — | — |
| 2026-06-08 | Sarah A. Teichmann | Director | A | — | — |
| 2026-06-08 | Kimberly J Popovits | Director | A | — | — |
| 2026-06-08 | Sridhar Kosaraju | Director | A | — | — |
| 2026-05-27 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2026-05-27 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2026-05-27 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-04-16 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-03-25 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-03-04 | Serge Saxonov | Chief Executive Officer | MIXED | — | — |
| 2026-03-02 | Benjamin J. Hindson | See Remarks | A | — | — |
| 2026-03-02 | Serge Saxonov | Chief Executive Officer | A | — | — |
| 2026-03-02 | Adam Taich | Chief Financial Officer | A | — | — |
| 2026-02-27 | Sarah A. Teichmann | Director | Sell | — | — |
| 2026-02-25 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2026-02-25 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2026-02-25 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2026-01-07 | Serge Saxonov | Chief Executive Officer | M | — | — |
| 2025-11-25 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2025-11-25 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2025-11-25 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2025-09-16 | Serge Saxonov | Chief Executive Officer | G | — | — |
| 2025-08-26 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2025-08-26 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2025-08-26 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2025-06-11 | Serge Saxonov | Chief Executive Officer | G | — | — |
| 2025-06-05 | SHEHNAAZ SULIMAN | Director | A | — | — |
| 2025-06-05 | JOHN R STUELPNAGEL | Director | A | — | — |
| 2025-06-05 | ALAN MATEO | Director | A | — | — |
| 2025-06-05 | Sarah A. Teichmann | Director | A | — | — |
| 2025-06-05 | Sridhar Kosaraju | Director | A | — | — |
| 2025-06-05 | Kimberly J Popovits | Director | A | — | — |
| 2025-06-02 | Serge Saxonov | Chief Executive Officer | G | — | — |
| 2025-05-27 | Adam Taich | Chief Financial Officer | Sell | — | — |
| 2025-05-27 | Benjamin J. Hindson | See Remarks | Sell | — | — |
| 2025-05-27 | Serge Saxonov | Chief Executive Officer | Sell | — | — |
| 2025-03-19 | Benjamin J. Hindson | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,618,151 | — |
| — | Director | 3,878,925 | — |
| — | 10%+ Owner | 3,836,232 | — |
| — | 10%+ Owner | 3,500,000 | — |
| — | 10%+ Owner | 2,306,517 | — |
| — | 10%+ Owner | 1,500,000 | — |
| — | 10%+ Owner | 1,287,825 | — |
| — | Chief Executive Officer | 1,146,993 | — |
| — | See Remarks | 488,182 | — |
| — | Chief Financial Officer | 362,732 | — |
| — | Director | 351,436 | — |
| — | 10%+ Owner | 187,500 | — |
| — | Director | 180,259 | — |
| — | Chief Financial Officer | 143,242 | — |
| — | Chief Commercial Officer | 97,237 | — |
| — | Director | 85,877 | — |
| — | Chief Commercial Officer | 83,342 | — |
| — | Director | 68,278 | — |
| — | Director | 37,445 | — |
| — | Director | 30,331 | — |
| — | Director | 29,515 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TXG quote page; the site-wide leaderboard is on the insider transactions hub.